Delineation of the Prostate Bed: The “Invisible Target” Is Still an Issue?

  • Latorzeff I
  • Sargos P
  • Loos G
  • et al.
Citations of this article
Mendeley users who have this article in their library.


© 2017 Latorzeff, Sargos, Loos, Supiot, Guerif and Carrie. For pathological high-risk prostate cancer, adjuvant irradiation has shown a survival benefit. Phase III studies have highlighted that half men would face biochemical relapse and would be candidate for radiotherapy at adjuvant or salvage times. Despite at least four published international contouring guidelines from different collaborative groups, discrepancies remain for volumes, delineation, and margins to be considered in order to optimize radiotherapy planning. This article from "Groupe d'Etude des Tumeurs UroGénitales (GETUG)" members will focus on controversies to help clinicians to create best volume delineation for adjuvant or salvage post prostatectomy radiotherapy.




Latorzeff, I., Sargos, P., Loos, G., Supiot, S., Guerif, S., & Carrie, C. (2017). Delineation of the Prostate Bed: The “Invisible Target” Is Still an Issue? Frontiers in Oncology, 7.

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free